Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bordetella pertussis pertactin antigen (formaldehyde inactivated) is a vaccine component used in the prophylaxis of pertussis (whooping cough). It is one of several purified components of B. pertussis used in acellular pertussis vaccines. Pertactin is a virulence factor of B. pertussis that has been inactivated with formaldehyde for use in vaccines. This component is typically combined with other pertussis antigens (such as pertussis toxoid, filamentous hemagglutinin, and fimbriae) and often formulated with diphtheria and tetanus toxoids in combination vaccines like DTaP (Diphtheria, Tetanus, acellular Pertussis).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bordetella pertussis pertactin antigen (formaldehyde inactivated).